Literature DB >> 26276935

Antiphospholipid Syndrome--Not a Noninflammatory Disease.

Philip G de Groot1, Rolf T Urbanus1.   

Abstract

The autoimmune disease antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy morbidity in patients with persistent antiphospholipid antibodies (aPLs). Although inflammation is not a key feature of the clinical presentation of the syndrome, there are indications that the inflammatory response plays an important role in APS. The major antigen of aPLs, the plasma protein β2-glycoprotein I, is involved in clearance of microparticles and in the innate immune response. In light of these physiological functions, the formation of antibodies against the protein is easily understood, as antibodies might augment the clearance reaction. In addition, inflammatory mediators are thought to play a role in the activation of leukocytes and the induction of endothelial dysfunction in APS. Moreover, evidence for a role of complement activation in the pathogenesis of the syndrome is accumulating. This review will provide an overview of current knowledge on the physiological function of β2-glycoprotein I, the formation of autoantibodies against β2-glycoprotein I and will explore the contribution of inflammation to the clinical manifestations of APS. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26276935     DOI: 10.1055/s-0035-1556725

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  13 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 2.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

Review 3.  Antiphospholipid syndrome: an update for clinicians and scientists.

Authors:  Andrew P Vreede; Paula L Bockenstedt; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

4.  Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target.

Authors:  Jason S Knight; He Meng; Patrick Coit; Srilakshmi Yalavarthi; Gautam Sule; Alex A Gandhi; Robert C Grenn; Levi F Mazza; Ramadan A Ali; Paul Renauer; Jonathan D Wren; Paula L Bockenstedt; Hui Wang; Daniel T Eitzman; Amr H Sawalha
Journal:  JCI Insight       Date:  2017-09-21

5.  Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.

Authors:  Maria Laura Bertolaccini; Gregorio Contento; Ross Lennen; Giovanni Sanna; Philip J Blower; Michelle T Ma; Kavitha Sunassee; Guillermina Girardi
Journal:  J Autoimmun       Date:  2016-05-06       Impact factor: 7.094

6.  Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome.

Authors:  Lorena Alvarez-Rodriguez; Leyre Riancho-Zarrabeitia; Jime Calvo-Alén; Marcos López-Hoyos; Victor Martínez-Taboada
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

Review 7.  The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Authors:  Chris Wincup; Yiannis Ioannou
Journal:  Front Pediatr       Date:  2018-11-27       Impact factor: 3.418

8.  Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome.

Authors:  Lorena Álvarez-Rodríguez; Víctor Martínez-Taboada; Jaime Calvo-Alén; Iñaki Beares; Ignacio Villa; Marcos López-Hoyos
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

9.  Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?

Authors:  Giulia Ferrannini; Elisabet Svenungsson; Barbro Kjellström; Kerstin Elvin; Giorgia Grosso; Per Näsman; Lars Rydén; Anna Norhammar
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

Review 10.  Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis.

Authors:  Maria Letizia Urban; Alessandra Bettiol; Irene Mattioli; Alfredo Vannacci; Elena Silvestri; Domenico Prisco; Giacomo Emmi; Gerardo Di Scala; Laura Avagliano; Niccolò Lombardi; Giada Crescioli; Gianni Virgili; Caterina Serena; Federico Mecacci; Claudia Ravaldi
Journal:  Intern Emerg Med       Date:  2021-01-21       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.